"Biomarkers, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS.
| Descriptor ID |
D014408
|
| MeSH Number(s) |
D23.101.140
|
| Concept/Terms |
Biomarkers, Tumor- Biomarkers, Tumor
- Tumor Biomarkers
- Markers, Biological Tumor
- Tumor Markers, Biological
- Markers, Tumor Metabolite
- Tumor Metabolite Markers
- Metabolite Markers, Tumor
- Marker, Tumor Metabolite
- Metabolite Marker, Tumor
- Tumor Metabolite Marker
- Tumor Markers, Biologic
- Biologic Tumor Markers
- Markers, Biologic Tumor
- Marker, Biologic Tumor
- Biologic Tumor Marker
- Tumor Marker, Biologic
- Biochemical Tumor Markers
- Markers, Biochemical Tumor
- Marker, Biochemical Tumor
- Biochemical Tumor Marker
- Tumor Marker, Biochemical
- Tumor Markers, Biochemical
- Carcinogen Markers
- Markers, Carcinogen
- Markers, Neoplasm Metabolite
- Neoplasm Metabolite Markers
- Marker, Neoplasm Metabolite
- Metabolite Marker, Neoplasm
- Neoplasm Metabolite Marker
- Metabolite Markers, Neoplasm
- Biological Tumor Markers
- Biological Tumor Marker
- Tumor Marker, Biological
- Marker, Biological Tumor
Markers, Tumor- Markers, Tumor
- Tumor Markers
- Biomarkers, Cancer
- Cancer Biomarkers
|
Below are MeSH descriptors whose meaning is more general than "Biomarkers, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Biomarkers, Tumor".
This graph shows the total number of publications written about "Biomarkers, Tumor" by people in this website by year, and whether "Biomarkers, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 17 | 10 | 27 |
| 1995 | 15 | 7 | 22 |
| 1996 | 11 | 16 | 27 |
| 1997 | 15 | 15 | 30 |
| 1998 | 24 | 30 | 54 |
| 1999 | 21 | 28 | 49 |
| 2000 | 21 | 36 | 57 |
| 2001 | 43 | 33 | 76 |
| 2002 | 40 | 47 | 87 |
| 2003 | 52 | 63 | 115 |
| 2004 | 69 | 57 | 126 |
| 2005 | 79 | 80 | 159 |
| 2006 | 81 | 78 | 159 |
| 2007 | 91 | 70 | 161 |
| 2008 | 95 | 73 | 168 |
| 2009 | 102 | 88 | 190 |
| 2010 | 86 | 120 | 206 |
| 2011 | 118 | 118 | 236 |
| 2012 | 119 | 116 | 235 |
| 2013 | 134 | 97 | 231 |
| 2014 | 150 | 102 | 252 |
| 2015 | 148 | 104 | 252 |
| 2016 | 155 | 139 | 294 |
| 2017 | 151 | 131 | 282 |
| 2018 | 113 | 132 | 245 |
| 2019 | 141 | 126 | 267 |
| 2020 | 131 | 128 | 259 |
| 2021 | 110 | 119 | 229 |
| 2022 | 7 | 101 | 108 |
| 2023 | 5 | 76 | 81 |
| 2024 | 62 | 98 | 160 |
To return to the timeline,
click here.
Below are the most recent publications written about "Biomarkers, Tumor" by people in Profiles.
-
A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study. Clin Cancer Res. 2024 Dec 02; 30(23):5304-5313.
-
HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01. Nat Commun. 2024 Nov 25; 15(1):10213.
-
Redefining pancreatic cancer management with tumor-agnostic precision medicine. Carcinogenesis. 2024 Nov 22; 45(11):836-844.
-
Clear cell stromal tumor of the lung: Report of 3 cases with emphasis on multifocal tumors. Pathol Res Pract. 2024 Dec; 264:155722.
-
DNA methylation classifier to diagnose pancreatic ductal adenocarcinoma metastases from different anatomical sites. Clin Epigenetics. 2024 Nov 10; 16(1):156.
-
PIT-1/SF-1 co-expression in pituitary neuroendocrine tumors (PitNETs) with comprehensive review of the literature: How should we best characterize these neoplasms? Ann Diagn Pathol. 2025 Feb; 74:152398.
-
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer. Cell Rep Med. 2024 Nov 19; 5(11):101799.
-
Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer. Clin Cancer Res. 2024 Nov 01; 30(21):4932-4942.
-
National Liver Cancer Screening Trial (TRACER) study protocol. Hepatol Commun. 2024 Nov 01; 8(11).
-
Glycosylation in cancer as a source of biomarkers. Expert Rev Proteomics. 2024 Sep-Oct; 21(9-10):345-365.